申请人:Sterling Drug Inc.
公开号:US04317827A1
公开(公告)日:1982-03-02
Disclosed and claimed are a cardiac composition and a method for increasing cardiac contractility using an effective amount of a cardiotonic 4-[4-(or 3)-AcNH-phenyl]-2-R.sub.2 -3-R.sub.3 -5-R.sub.5 -6-R.sub.6 -pyridine (I) or pharmaceutically-acceptable salt thereof, where R.sub.2 is hydrogen, methyl, ethyl or hydroxyl, R.sub.6 is hydrogen, methyl or ethyl, R.sub.3 and R.sub.5 are each hydrogen or methyl, and Ac is hydrogen, hydroxyacetyl, acetoxyacetyl, .alpha.-hydroxypropionyl, .alpha.-acetoxypropionyl, methyoxyacetyl, 2-butenoyl or carbamyl or when NHAc is attached to the 4-position of the phenyl ring Ac also is formyl, n-propanoyl, 2,2-dimethyl-n-propanoyl or 3-carboxypropanoyl or when NHAc is attached to the 3-position of the phenyl ring Ac also is acetyl. Novel compounds shown and claimed are 4-[4-(or 3)-Ac'NH-phenyl]-2-R.sub.2 -3-R.sub.3 -5-R.sub.5 -6-R.sub.6 -pyridines (II) or pharmaceutically-acceptable acid-addition salts thereof, where R.sub.2, R.sub.3, R.sub.5 and R.sub.6 are defined as above for I and Ac' is hydroxyacetyl, acetoxyacetyl, .alpha.-hydroxypropanoyl, .alpha.-acetoxypropionyl, methoxyacetyl, 2-butenoyl or carbamyl or where Ac'NH is attached to the 4-position of the phenyl ring Ac' also is formyl, n-propanoyl, 2,2-dimethyl-n-propanoyl or 3-carboxypropanoyl. Also disclosed and claimed is the process for preparing said novel compounds (II).
公开并声明了一种心脏组成物和使用有效量的心力血药4-[4-(或3)-AcNH-苯基]-2-R.sub.2-3-R.sub.3-5-R.sub.5-6-R.sub.6-吡啶(I)或其药用可接受盐的增加心脏收缩力的方法,其中R.sub.2为氢、甲基、乙基或羟基,R.sub.6为氢、甲基或乙基,R.sub.3和R.sub.5分别为氢或甲基,Ac为氢、羟乙酰基、乙酰氧基、α-羟基丙酰基、α-乙酰氧基丙酰基、甲氧基乙酰基、2-丁烯酰基或氨基甲酰基,或者当NHAc连接到苯环的4位时,Ac也是甲酰基、正丙酰基、2,2-二甲基正丙酰基或3-羧基丙酰基,或者当NHAc连接到苯环的3位时,Ac也是乙酰基。显示和声明的新化合物是4-[4-(或3)-Ac'NH-苯基]-2-R.sub.2-3-R.sub.3-5-R.sub.5-6-R.sub.6-吡啶(II)或其药用可接受酸加合物盐,其中R.sub.2、R.sub.3、R.sub.5和R.sub.6如上所述,Ac'为羟乙酰基、乙酰氧基、α-羟基丙酰基、α-乙酰氧基丙酰基、甲氧基乙酰基、2-丁烯酰基或氨基甲酰基,或者当Ac'NH连接到苯环的4位时,Ac'也是甲酰基、正丙酰基、2,2-二甲基正丙酰基或3-羧基丙酰基。还公开并声明了制备所述新化合物(II)的过程。